China Pioneer Pharma Takes the First Move to Rekindle Patients' Hopes
HONG KONG, Apr 1, 2015 - (ACN Newswire) - China Pioneer Pharma Holdings Limited ("China Pioneer Pharma" or the "Company" or the "Group"; stock code: 01345), one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China, is pleased to announce that NeutroPhase, a skin and wound cleanser exclusively marketed, promoted and distributed by the Group in mainland China and parts of Southeast Asia, was recently named as the official wound cleanser of the National Necrotizing Fasciitis Foundation (NNFF) in the United States. The Group has already teamed up with NNFF and the product manufacturer - NovaBay Pharmaceuticals, Inc. to offer NeutroPhase and relevant medical guidance at no charge to patients who suffer from flesh-eating disease in the region in order to enable doctors to save life of patients as quick as possible and to curb the deterioration of the situation to avoid the need for amputation.
China Pioneer Pharma first introduced NeutroPhase in mainland China in September 2014 to patients who suffered from diabetic foot ulcers and burns for clinical trial applications for a short period of time. The cleanser was immediately recognized by both the doctors and patients. A number of doctors, such as Dr. Yang Qianyong and Dr. Li Qi, Directors of Department of Endocrinology of Chinese People's Liberation Army No. 94 Hospital, and Dr. Hao Jianhua, Orthopedic physician of Chinese People's Liberation Army No. 254 Hospital and so on, approbates NeutroPhase for its significant medical effects on the diabetic foot ulcers wounds with accolades and commendations.
NeutroPhase was pioneered for the treatment of necrotizing fasciitis. It does not only kill bacteria, but also neutralizes the toxins produced by both bacteria and the immune system, stopping the spread of dead tissue.
Mr. LI Xinzhou, Chairman and Executive Director of China Pioneer Pharma said: "NeutroPhase being named the official wound cleanser of the NNFF can further recognize its active ingredients, rekindles hopes for flesh-eating disease patients and bring major improvement in global medical care industry. Looking ahead, we will continue to provide NeutroPhase and relevant medical guidance to patients in need and lead them on the road to recovery."
About China Pioneer Pharma Holdings Limited China Pioneer Pharma is one of the leading comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. The Group was established in 1996, and was listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 01345) on 5 November 2013. The Company has strategically focused on providing comprehensive marketing, promotion and channel management services to small and medium sized overseas suppliers, and is generally the sole provider of such services in China for the relevant products. China Pioneer Pharma runs a diversified range of imported products (substantially all of which are prescription products), covering ophthalmology, pain management, cardiovascular, respiratory, gastroenterology, immunology and other therapeutic areas and a range of medical devices covering four medical specialties, including ophthalmology, odontology and wound care. The Company has also secured marketing, promotion and sales rights for 14 additional prescription pharmaceutical products and over 20 additional medical devices, which are in the registration process under China Food and Drug Administration for their importation and sales in China. As of 31 December 2014, the Company sold products through its nationwide marketing, promotion and channel management services networks to over 28,500 hospitals and other medical institutions and over 102,000 pharmacies across 31 provinces, municipalities and autonomous regions in China.
About NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide compounds, led by auriclosene, and its Hypochlorous Acid Family of Products, led by NeutroPhase. The Hypochlorous Acid Family of products includes NeutroPhase for wound care, as well as two new recently introduced products: Advanced i-Lid Cleanser for the eye care market and CelleRx for the dermatology market.
About the National Necrotizing Fasciitis Foundation The National Necrotizing Fasciitis Foundation (NNFF) is a non-profit organization established in 1997 by two survivors of the disease, which is dedicated to becoming the world's leading resource for information regarding necrotizing fasciitis, as well as repository of cases reported worldwide. Its mission is to educate for public awareness regarding recognition of symptoms and preventative measures and to offer support for those affected by necrotizing fasciitis.
Issued by Porda Havas International Finance Communications Group for and on behalf of China Pioneer Pharma Holdings Limited. For further information, please contact:
Porda Havas International Finance Communications GroupMr. Paul Sham +852 3150 6730 paul.sham@pordahavas.comMs. Susan Chen +852 3150 6733 susan.chen@pordahavas.comMr. Daniel Ip +852 3150 6767 daniel.ip@pordahavas.comMs. Amanda Zhao +852 3150 6769 amanda.zhao@pordahavas.comMs. Jessica Li +852 3150 6702 jessica.li@pordahavas.comFax: +852 3150 6728
Source: China Pioneer Pharma Holdings Limited
Copyright 2015 ACN Newswire . All rights reserved.
